The risk of hyperplasia or endometrial cancer

The risk of hyperplasia or endometrial cancer is effectively counteracted by the association of estrogen with progesterone (Albright, 2000).

At per menopause, on average up to 4 years before the full stop menses, the patient usually seeks the doctor complaining of irregular bleeding.for more details click here http://blog.ideafit.com/blogs/somanabolicmuscle1/somanabolic-muscle-maximizer-skin-care-with-acne

 The primary goal of therapy in these patients is the restoration of menstrual regularity.

In these cases, the use of cyclic progestin is the most appropriate treatment

 Hormone Replacement Therapy (HRT) is the conventional administration of estrogens alone, and so indeed it is a Estrogen Replacement Therapy (ERT).

 This TRE is only used in women hysterectomy (no uterus) or associated with progestins, when you want to protect the endometrial. A Hormone

Replacement Therapy (HRT) combined can be used cyclically or continuously.

In a cyclical estrogen is administered continuously for 21 days or monthly, whereas progesterone is administered only during 10 to 14 days.

for more information visit here http://blog.ideafit.com/blogs/somanabolicmuscle1/somanbolic-muscle-maximizer-by-fat-secretions

 The suspension of progesterone normally cause menstrual bleeding, therefore, is a preferred scheme premenopausal or in early post menopause.

On a continuous combined HRT patient to receive associated with daily estrogen and progestin, developing endometrial atrophy and therefore no monthly withdrawal bleeding. This is the preferred form of HRT in postmenopausal women later. Another option for the treatment of postmenopausal women is tibolone (which is a synthetic steroid that is not estrogen or progesterone but nevertheless properties estrogenic and androgenic.

for more details click here http://blog.ideafit.com/blogs/somanabolicmuscle1/somanabolic-muscle-maximizer-fats-with-acne